Currently, Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. This represents no change from the previous week and is the same ranking VRTX has had from Portfolio Grader for 4 months.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a member of the 350 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. The market value of VRTX is $35.6 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader score places it 32 among the 350 companies in this industry group, positioning it among the leaders; in the top quartile of the sector with a ranking of 102 among the 782 companies in the sector, and number 591 in the nearly 5,000 company Portfolio Grader universe.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is ranked as a Buy using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking VRTX has had from Portfolio Grader for 4 months.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 781 company GICS Health Care sector. VRTX's market value is $37.2 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for VRTX puts it 60 among the 349 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 158 among the 781 companies in the sector, and number 1,038 in the nearly 5,000 company Portfolio Grader universe.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is ranked as a Buy using Louis Navellier's methods for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 4 months.

As one of the 785 companies in the GICS Health Care sector Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a member of the 349 company Biotechnology GICS industry group within this sector. VRTX's market value is $37.9 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for VRTX puts it 81 among the 349 companies in this industry group, putting in the top quartile; in the top half of the sector with a ranking of 222 among the 785 companies in the sector, and number 1,463 in the nearly 5,000 company Portfolio Grader universe.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is classified as a member of the 345 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. VRTX has a market value of $38.8 billion which is in the top 10% of its industry group. Portfolio Grader's current ranking for VRTX puts it 40 among the 345 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 133 among the 782 companies in the sector, and number 983 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is derived using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. VRTX has maintained this ranking for 3 months.

The current recommendation of Buy for Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is the result of using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. VRTX has maintained this ranking for 2 months.

The current recommendation of Buy for Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is the result of using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. VRTX has maintained this ranking for 2 months.